Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis-A meta-analysis

Vaccine

Volumn 27, Issue 35, 2009, Pages 4747-4753

  Noazin, Sassan ^a   Khamesipour, Ali ^b   Moulton, Lawrence H ^c   Tanner, Marcel ^d   Nasseri, Kiumarss ^e   Modabber, Farrokh ^b,f,h,k   Sharifi, Iraj ^g   Khalil, E A G ^h   Bernal, Ivan Dario Velez ⁱ   Antunes, Carlos M F ^j   Smith, Peter G ^k  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e Public Health Institute   (United States)

^f Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

^g KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h UNIVERSITY OF KHARTOUM   (Sudan)

ⁱ UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^j FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^k LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

Clinical trial; Leishmaniasis vaccine; Meta analysis

Indexed keywords

INACTIVATED VACCINE; LEISHMANIA VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNITY; LEISHMANIASIS; META ANALYSIS; PARASITE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SYSTEMATIC REVIEW; VACCINATION;

ANIMALS; HUMANS; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, INACTIVATED;

EID: 67650506229     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.084     Document Type: Review

References (35)

1. Davies C.R., Kaye P., Croft S.L., and Sundar S. Leishmaniasis: new approaches to disease control. BMJ 326 7385 (2003) 377-382
2. WHO. Leishmaniasis Home Page. World Health Organization website, 8-21-2006, http://www.who.int/leishmaniasis/burden/en/. (GENERIC) Ref Type: Electronic Citation.
3. WHO. Urbanization: an increasing risk factor for leishmaniasis (Weekly Epidemiological Report) vol. 44 (2002), World Health Organization, Geneva p. 365 [The Weekly Epidemiological Record (WER)]
4. Dantas-Torres F., and Brandao-Filho S.P. Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control. Rev Inst Med Trop Sao Paulo 48 3 (2006) 151-156
5. Gafurov I.M. Experience in controlling and preventing zoonotic cutaneous leishmaniasis in Uzbekistan. Med Parazitol (Mosk) 1 (1999) 58-59
6. Thakur C.P., and Kumar K. Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes. Ann Trop Med Parasitol 86 4 (1992) 355-359
7. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 6 11 (2001) 928-934
8. Croft S.L., and Coombs G.H. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19 11 (2003) 502-508
9. Croft S.L., Sundar S., and Fairlamb A.H. Drug resistance in leishmaniasis. Clin Microbiol Rev 19 1 (2006) 111-126
10. Dube A., Singh N., and Sundar S. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 96 4 (2005) 216-223
11. Hadighi R., Mohebali M., Boucher P., Hajjaran H., Khamesipour A., and Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 3 5 (2006) 659-667
12. Khalil E.A., el Hassan A.M., Zijlstra E.E., Hashim F.A., Ibrahim M.E., Ghalib H.W., et al. Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond. Ann Trop Med Parasitol 92 2 (1998) 151-158
13. Ahluwalia I.B., Bern C., Costa C., Akter T., Chowdhury R., Ali M., et al. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg 69 6 (2003) 624-628
14. WHO/TDR. Generating evidence to improve the effectiveness of control programmes (Report of the Scientific Working Group on Leishmaniasis). Geneva, Switzerland. World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases; 2004.
15. Khamesipour A., Dowlati Y., Asilian A., Hashemi-Fesharki R., Javadi A., Noazin S., et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23 28 (2005) 3642-3648
16. Nadim A., Javadian E., Tahvildar-Bidruni G., and Ghorbani M. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales 76 4 (1983) 377-383
17. Nadim A., Javadian E., and Mohebali M. The experience of leishmanization in the Islamic Republic of Iran. East Mediterr Health J 3 2 (1997) 284-289
18. Khamesipour A., Rafati S., Davoudi N., Maboudi F., and Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 123 3 (2006) 423-438
19. Genaro O., de Toledo V.P., da Costa C.A., Hermeto M.V., Afonso L.C., and Mayrink W. Vaccine for prophylaxis and immunotherapy, Brazil. Clin Dermatol 14 5 (1996) 503-512
20. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14 2 (2001) 229-243
21. Armijos R.X., Weigel M.M., Aviles H., Maldonado R., and Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 177 5 (1998) 1352-1357
22. Bahar K., Dowlati Y., Shidani B., Alimohammadian M.H., Khamesipour A., Ehsasi S., et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol 14 5 (1996) 489-495
23. Dowlati Y., Ehsasi S., Shidani B., and Bahar K. Stepwise safety trial of a killed Leishmania vaccine in Iran. Clin Dermatol 14 5 (1996) 497-502
24. Khalil E.A., el Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356 9241 (2000) 1565-1569
25. Momeni A.Z., Jalayer T., Emamjomeh M., Khamesipour A., Zicker F., Ghassemi R.L., et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17 5 (1999) 466-472
26. Noazin S., Modabber F., Khamesipour A., Smith P.G., Moulton L.H., Nasseri K., et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26 52 (2008) 6759-6767
27. Sharifi I., FeKri A.R., Aflatonian M.R., Khamesipour A., Nadim A., Mousavi M.R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351 9115 (1998) 1540-1543
28. Velez I.D., Gilchrist K., Arbelaez M.P., Rojas C.A., Puerta J.A., Antunes C.M.F., et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans R Soc Trop Med Hyg 99 8 (2005) 593-598
29. Antunes C.M., Mayrink W., Magalhaes P.A., Costa C.A., Melo M.N., Dias M., et al. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 15 4 (1986) 572-580
30. Convit J., Castellanos P.L., Rondon A., Pinardi M.E., Ulrich M., Castes M., et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1 8530 (1987) 401-405
31. Machado-Pinto J., Pinto J., da Costa C.A., Genaro O., Marques M.J., Modabber F., et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int J Dermatol 41 2 (2002) 73-78
32. Armijos R.X., Weigel M.M., Calvopina M., Hidalgo A., Cevallos W., and Correa J. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 22 9-10 (2004) 1320-1326
33. Deeks J, Altman D, Bradburn MJ, Egger M, Davey Smith G, Altman D, editors. Systematic reviews in health care: meta-analysis in context. 5. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. 2nd ed. London: BMJ Publishing Group; 2005. p. 43-68.
34. Huedo-Medina T.B., Sanchez-Meca J., Marin-Martinez F., and Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I-2 index?. Psychol Methods 11 2 (2006) 193-206
35. Alimohammadian M.H., Khamesipour A., Darabi H., Firooz A., Malekzadeh S., Bahonar A., et al. The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine 21 3-4 (2002) 174-180